Triplet produces ‘unprecedented’ ORR in PI-refractory MM
November 20, 2018|Hematology and Oncology
This work was supported by the Swiss Group for Clinical Cancer Research, the Swiss State Secretariat for Education, Research and Innovation, the Rising Tide Foundation for Clinical Cancer Research, and the Gateway for Cancer Research.
Most of the researchers declared no competing financial interests, but one reported personal fees from Celgene, Takeda, Amgen, Novartis, and Janssen-Cilag that were unrelated to this trial.
1. Lokhorst HM et al. N Engl J Med. 2015; 373(13):1207-1219.
